– Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
– Alkem is introducing anti-counterfeit band and important patient education information on empagliflozin packs
– Alkemis offeringempagliflozin in a smaller tablet size, making it convenient for patients
Alkem Laboratories Ltd (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries), today announced the launch of generic empagliflozin and its combinations in India under the brand name “Empanorm” at prices that are approximately 80% lower than the innovator products.
Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2)inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). Alkem’s generic empagliflozin and its combinations are bioequivalent to innovator products.
With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infographics, and QR codes that provide prescribing information and additional patient educationinformation on diabetes, heart failure, and chronic kidney disease in 11 languages.
Keeping patient-convenience in mind, Alkem is offering the medicine in a considerably smaller tablet size than the innovator products.
Alkem’s generic empagliflozin is available under the brand name “Empanorm” and its combinations namely: (i) empagliflozin and linagliptin is available under the name “Empanorm L”; (ii) empagliflozin and sitagliptin is available under the name “Empanorm Duo” and “Alsita E”; and (iii) empagliflozin and metformin is available under the name “Empanorm M”.
Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone. This globally-accepted molecule has transformed diabetes care with its additional benefits in managing chronic kidney disease and cardiovascular health.Leveraging Alkem’s strong distribution network, we aim to make this therapy widely available, enhancing treatment accessibility and improving health outcomes for patients across the country.”